Ignite Creation Date:
2025-12-24 @ 4:58 PM
Ignite Modification Date:
2026-01-02 @ 1:30 PM
Study NCT ID:
NCT05781750
Status:
TERMINATED
Last Update Posted:
2025-12-05
First Post:
2023-03-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
Sponsor:
Kezar Life Sciences, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lupus Nephritis | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | immunoproteasome inhibition | View |
| None | selective immunoproteasome inhibition | View |
| None | complete renal response | View |
| None | partial renal response | View |
| None | glucocorticoids | View |
| None | steroids | View |
| None | SLE (systemic lupus erythematosus) | View |
| None | UPCR (urine protein to creatinine ratio) | View |
| None | eGFR (estimated glomerular filtration rate) | View |